PUBLIC COMPANY
save$RVMDRevolution Medicines, Inc.
$RVMD159.43-0.24%Redwood City, CA, USupdated 8h ago
community read0 votes
pipeline
2
marketed
0
phase 3
1
catalysts ytd
4
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 21Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase3Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- phase2Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
- phase2Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- phase3Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
- phase3Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
- phase2Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- phase3Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
- —Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
🐶 Hiring Signal
Where Revolution Medicines, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaOncology 344CNS / Neuroscience 1
News
- RevMed’s Rasonque shatters analyst estimates with $198M quarterPent-up demand for the new pancreatic cancer therapy Rasonque helped RevMed soar past analysts’ sales expectations and reach 5,000 patients in the third quarter.biospace · 14d ago
- Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdictWith companies including AstraZeneca, Pfizer and Revolution Medicines clamoring to get in on Summit Therapeutics’ Akeso-partnered PD-1xVEGF antibody, one analyst calls the asset “the next major bac…biospace · 17d ago
- Alphabet’s GV is one of biotech’s most influential corporate investorsThe corporate investor arms of Eli Lilly, Sanofi and Pfizer have participated in billions worth of venture capital rounds, but GV is the industry’s biggest spender.biospace · 23d ago
- STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMOA targeted drug from Incyte, when used in combination with chemotherapy, induced lasting tumor responses in certain patients with pancreatic cancer.stat · 24d ago
- Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness studyRoche is paying Hansoh $400 million up front in a broad deal involving several ADCs. Elsewhere, another top investor formed a China-focused fund and Ultragenyx sold a second review voucher.biopharma_dive · 1mo ago
- Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on Merck and Moderna’s personalized cancer vaccine, Summit and Akeso’s PD-1xV…biospace · 1mo ago
- Iambic goes public with $150M IPO to accelerate clinical development of oncology pipelineIambic Therapeutics’ IPO came in dead on target, bringing in $150 million for the AI biotech to fuel the clinical development of its oncology pipeline.fiercebiotech · 1mo ago
- J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutbackJohnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio bu…biospace · 1mo ago
- Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earningsBellwether Johnson & Johnson will kick off the third quarter earnings reporting period on Tuesday, with analysts searching for news on business development, launch execution and more.biospace · 1mo ago
- New data on RevMed’s Rasonque leave potential opening for other treatmentsPatients with the most common KRAS mutation in pancreatic cancer appeared to have a lower response rate than the overall patient population with Revolution Medicines’ Rasonque, sending the company’…endpoints · 1mo ago
Data sources
last refreshed 27m ago
Found something off?
comments(0)
5-min edit window · permanent after that